Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page
- Check5 days agoChange DetectedThe NCT03650894 record now presents details of a Phase 2 breast cancer study, including its treatments, eligibility criteria, locations, and outcome measures. It also includes study status and record dates, collaborators, and related resources.SummaryDifference52%

- Check12 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 error.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA site-wide notice about NIH terminology changes appears above the error page, and the footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check54 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the study record content. Previous content including locations, institutions, and study details has been removed and replaced by a simple error page with only a Home link.SummaryDifference19%

- Check61 days agoChange DetectedThe page's revision label was updated from Revision: v3.6.6 to Revision: v3.7.0, indicating a maintenance/upgrade of the ClinicalTrials.gov interface for this record. The study information and controls remain the same.SummaryDifference0.1%

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.